| Followers | 9888 |
| Posts | 261364 |
| Boards Moderated | 4 |
| Alias Born | 12/27/2006 |
Monday, May 20, 2019 5:52:29 PM
* * $OGEN Video Chart 05-20-2019 * *
Link to Video - click here to watch the technical chart video
Link to Video - click here to watch the technical chart video
Recent OGEN News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/20/2026 08:10:28 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/20/2026 08:05:37 PM
- Sidoti Events, LLC's May Micro-Cap Virtual Conference • ACCESS Newswire • 05/20/2026 11:30:00 AM
- Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21 • GlobeNewswire Inc. • 05/19/2026 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/19/2026 12:38:18 PM
- ORAGENICS PROVIDES INVESTOR UPDATE • GlobeNewswire Inc. • 05/18/2026 12:30:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/08/2026 08:05:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2026 08:01:53 PM
- Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation • GlobeNewswire Inc. • 05/07/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 12:15:28 PM
- Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury. • GlobeNewswire Inc. • 05/05/2026 12:30:00 PM
- Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury • GlobeNewswire Inc. • 04/20/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/13/2026 12:30:17 PM
- Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury • GlobeNewswire Inc. • 04/13/2026 12:30:00 PM
- Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation • GlobeNewswire Inc. • 03/25/2026 10:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/23/2026 04:15:07 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 03/19/2026 09:24:57 PM
- ORAGENICS FILES ANNUAL REPORT ON FORM 10-K • GlobeNewswire Inc. • 03/17/2026 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/16/2026 08:30:41 PM
- ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION • GlobeNewswire Inc. • 03/12/2026 12:30:00 PM
- ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION • GlobeNewswire Inc. • 03/11/2026 12:30:00 PM
- Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia • GlobeNewswire Inc. • 03/10/2026 12:30:00 PM
- Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy • GlobeNewswire Inc. • 02/09/2026 01:30:00 PM
- Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care • GlobeNewswire Inc. • 02/02/2026 01:30:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/22/2026 09:11:24 PM
